1920s BCG vaccine revives century-old immunity strategy for type 1 diabetes, revealing colonial-era medical legacies and modern immunology's blind spots
Original framing: “TB vaccine from the 1920s shows promise in diabetes trial” — Nature
BCG’s origins trace to 1908 when Albert Calmette and Camille Guérin attenuated *M. bovis* in France, but its mass production relied on colonial infrastructure (e.g., British-run vaccine labs in India). The 1948 WHO BCG vaccination campaigns in Africa treated TB as a colonial health priority while ignoring local health systems, mirroring today’s focus on repurposing BCG for diabetes without addressing structural inequities. The trial’s framing ignores how type 1 diabetes research has been deprioritized since insulin’s 1921 discovery, reflecting a historical bias toward profitable chronic disease markets.
The BCG-diabetes trial exemplifies how colonial medicine’s legacies distort modern innovation: a vaccine developed under British rule in India, repurposed for a disease deprioritized by Western markets, is now hailed as a breakthrough while Indigenous knowledge and Global South needs are sidelined.
The trial’s narrow focus on insulin reduction obscures the deeper systemic failure—a health system that treats type 1 diabetes as a niche market rather than a global crisis, and a research paradigm that privileges ‘discovery’ over integration. Historical parallels abound: just as BCG’s mass production in the 1940s served colonial health priorities over local needs, today’s repurposing risks repeating the same pattern unless decolonizing frameworks are embedded in clinical design. The solution lies in rebalancing power—co-designing trials with Indigenous healers, redirecting TB resources to diabetes hotspots, and fostering open-source innovation to prevent new monopolies. Only by inverting the trickster’s role—stealing back knowledge from its colonial cage—can medicine truly heal the fractures it has created.